Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

24.23USD
2:29am IST
Change (% chg)

$-0.49 (-1.98%)
Prev Close
$24.72
Open
$25.00
Day's High
$25.30
Day's Low
$22.98
Volume
1,231,479
Avg. Vol
110,750
52-wk High
$33.21
52-wk Low
$21.35

Latest Key Developments (Source: Significant Developments)

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.  Full Article

Aclaris Therapeutics says qtrly loss per share $0.63
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aclaris Therapeutics Inc -:Aclaris Therapeutics reports third quarter 2017 financial results.Aclaris Therapeutics Inc - qtrly loss per share $0.63.Aclaris Therapeutics Inc - qtrly revenue of $684,000.Aclaris Therapeutics Inc- ‍cash burn for 2017 is now estimated to be in range of $56 million to $59 million​.Aclaris Therapeutics Inc- ‍research and development expenses for 2017 are now estimated to be in range of $39 million to $42 million​.  Full Article

Aclaris Therapeutics qtrly loss per share $0.50
Thursday, 3 Nov 2016 

Aclaris Therapeutics Inc : Qtrly loss per share $0.50 .Aclaris therapeutics reports third quarter 2016 financial results.  Full Article

Aclaris Therapeutics Qtrly loss per share $0.62
Thursday, 11 Aug 2016 

Aclaris Therapeutics Inc : Aclaris Therapeutics reports second quarter 2016 financial results .Qtrly loss per share $0.62.  Full Article

Aclaris Therapeutics to resale up to 1.1 mln shares by selling stockholders
Saturday, 18 Jun 2016 

Aclaris Therapeutics Inc : Files resale of up to 1.1 million shares of co's common stock by by the selling stockholders Source: (http://1.usa.gov/23gMebL ) Further company coverage: [ACRS.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Aclaris Therapeutics announces $20 mln private placement
Friday, 27 May 2016 

Aclaris Therapeutics Inc : Aclaris Therapeutics announces $20.0 million private placement . Entered into stock purchase agreement for private placement of 1.1 million shares of stock at a purchase price of $18.50 per share .Net proceeds from offering are expected to be used to fund research and development, including new JAK inhibitor programs.  Full Article

Aclaris Therapeutics Q1 loss per share $0.65
Wednesday, 11 May 2016 

Aclaris Therapeutics Inc : Qtrly net loss attributable to common stockholders was $13.0 million for q1 of 2016, compared to $3.3 million . Qtrly loss per share $0.65 . Q1 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S .Aclaris Therapeutics reports first quarter 2016 financial results.  Full Article

Aclaris Therapeutics acquires worldwide rights to compounds and Key intellectual property for potential treatment for hair loss
Tuesday, 29 Mar 2016 

Aclaris Therapeutics:Has entered into an agreement with the stockholders of Vixen Pharmaceuticals Inc to acquire all of the stock of Vixen.  Full Article

Aclaris's drug to treat common skin growth gets FDA nod

Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.